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M𝜙 proliferation, differentiation, and survival are controlled by signals from the M𝜙 CSF recep-
tor (CSF1R). Mono-allelic gain-of-function mutations in CSF1R in humans are associated with
an autosomal-dominant leukodystrophy and bi-allelic loss-of-function mutations with reces-
sive skeletal dysplasia, brain disorders, and developmental anomalies. Most of the phenotypes
observed in these human disease states are also observed in mice and rats with loss-of-function
mutations inCsf1ror inCsf1encodingoneof its two ligands. Studies in rodentmodels alsohighlight
the importance of genetic background and likely epistatic interactions between Csf1r and other
loci. The impacts of Csf1r mutations on the brain are usually attributed solely to direct impacts
on microglial number and function. However, analysis of hypomorphic Csf1rmutants in mice and
several other lines of evidence suggest that primary hydrocephalus and loss of the physiologi-
cal functions of M𝜙s in the periphery contribute to the development of brain pathology. In this
review, we outline the evidence that CSF1R is expressed exclusively in mononuclear phagocytes
and explore the mechanisms linking CSF1Rmutations to pleiotropic impacts on postnatal growth
and development.
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1 INTRODUCTION
M𝜙s are an abundant cell population in all major organs and adapt
at each location to perform specific functions in physiology and
homeostasis.1–4 M𝜙 proliferation and differentiation is controlled by
signals from theM𝜙CSF receptor (CSF1R), in response to 2 alternative
ligands, M𝜙 CSF1 and IL-34. M𝜙s generated in vitro from monocytes
or bone marrow progenitors, by cultivation in CSF1, have been widely
used as models for the study of M𝜙 biology in multiple species.5–8
In the mouse, M𝜙s also depend upon exogenous CSF1 for survival.9
In other species, including humans, rats, pigs, sheep, goats, cattle,
horses, water buffalo, and even chickens, CSF1 is induced during M𝜙
differentiation. Mature M𝜙s themselves express high levels of CSF1
mRNA and are effectively autocrine for the pro-survival signal (data in
ref. 10–13). Notwithstanding the apparent differences in expression
Abbreviations: ALSP, adult-onset leukoencephalophathy with axonal spheroids and pigmented glia; BMDM, bonemarrow-derivedM𝜙; GH, growth hormone .
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among species, the 2 functional ligands, CSF1 and IL-34 are conserved
across species from chicken and fish through to humans14–17 and an
intronic enhancer that regulates CSF1R expression is conserved from
reptiles to humans.18 The CSF1R gene was originally recognized by
its relationship to the transforming oncogene of a feline leukemia
virus19 and was known as the Fms protooncogene. Aside from the
functions in M𝜙s, in both mouse and human (and in other mammals;
www.biogps.org) CSF1R is also expressed in placental trophoblasts
driven by a separate promoter and transcription start site to those
used inM𝜙 lineage cells.20
In 2011, the human CSF1R gene was recognized as the site of
point mutations underlying autosomal dominant adult-onset leukoen-
cephalopathy with axonal spheroids and pigmented glia (ALSP)21
(MIM: 221820, also known as HDLS). Subsequent studies have
revealed many additional CSF1R mutations associated with ALSP
J Leukoc Biol. 2019;1–15. www.jleukbio.org 1
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(reviewed in ref. 22 and 23) and unified the diagnosis with a num-
ber of other disease entities with similar presentation (e.g., pigmented
orthochromatic leukodystrophy or POLD). The brain pathology and
symptoms of ALSP vary significantly between affected individuals
and the disease has been misdiagnosed antemortem as various other
dementias and neurodegenerative diseases. For example, Sassi et al.24
identified 3 likely pathogenic CSF1Rmutations in a cohort of 465 late-
onset Alzheimer’s patients.
A distinct recessive disease has more recently been associated
with loss-of-function alleles at the CSF1R locus.25,26 Patients lacking
CSF1R in the recessive disease had almost complete loss of microglia,
the M𝜙s of the brain, as well as defects in skeletal development and
osteosclerosis. As far aswe are aware, no patients have beendescribed
in whom there is homozygous loss-of-functionmutation in either CSF1
or IL34. The contact amino acids involved in interactions in the CSF1-
CSF1R and IL-34-CSF1R complexes have been dissected in crystal
structures.27,28 In the large human exome sequence collection ExAC
(exac.broadinstitute.org), there are no non-synonymous mutations
in CSF1 that potentially affect binding of CSF1 to the receptor, and
only 2 rare variants in IL-34 (E111K andW116G) that could alter IL34
binding. However, there is likely to be expression variation between
individuals. SNPs within the CSF1 locus have been associated with
Paget’s disease, an abnormality of bone resorption,29 most likely
associated with overexpression of CSF1 and excessive osteoclast acti-
vation. The level of circulating CSF1 in a very large cohort of coronary
artery disease patientswas correlatedwith distinct and relatively com-
mon cis-acting variants at theCSF1 locus and in turnwith susceptibility
to disease.30 In this article, we will critically review the interpretation
of studies of Csf1, Il34, and Csf1r mutations in experimental animals
and their relevance to the human genetic diseases.
1.1 The cell-type and tissue specificity of
Csf1r expression
A key piece of knowledge required to interpret the impact of Csf1r
mutations is the site of transcript and protein expression. Themain site
of expression ofCsf1r (aside fromexpression in placental trophoblasts)
is undoubtedly in cells of the monocyte-M𝜙 lineage. Reporter trans-
genes driven by the Csf1r promoter have been used to locate M𝜙s
throughout embryonic development and in tissues of adult mice,31–33
rats,34 sheep,35 and even chickens.14,15 The same mouse Csf1r pro-
moter driving Cre recombinase has also been used in lineage trace
experiments in the embryo36 without any evidence of expression out-
sidemyeloid lineages.
During mouse embryonic development, Csf1r mRNA is first
detected in the ectoplacental cone early after implantation and in
isolated M𝜙-like cells in the yolk sac.37 Localization of Csf1r mRNA
by whole mount in situ hybridization is consistent with restriction
to myeloid cells in the embryo.37 Although they are abundant and
actively involved in clearance of apoptotic cells,37 M𝜙s in the embryo
are not required for organogenesis. Ablation of Csf1r-dependent M𝜙s
by anti-CSF1R treatment of the mother has no effect on embryonic
development38 and Csf1r-deficient mice and rats are indistinguishable
from their littermates at birth.39,40
The restriction of Csf1r expression to cells of the M𝜙 lineage is also
supported by network analysis in both mouse and human systems. In
mouse development, the appearance of Csf1r mRNA is strongly cor-
related with expression of other known M𝜙 markers in a time course
of embryo gene expression.41 In the large promoter-based transcrip-
tomic atlas produced by the FANTOM Consortium, there is a sin-
gle cluster of M𝜙-specific transcription start sites in both mouse and
human.13 There is no detectable CSF1R expression in non-myeloid
primary cells or cell lines of multiple lineages. Interestingly, CSF1R
mRNA is also tightly correlated with a M𝜙 signature in gene expres-
sion profiles from a wide range of human solid tumors42 suggesting
that it is exclusively expressed by tumor-associated M𝜙s and ectopic
expression in tumor cells is not common. The molecular basis for M𝜙-
specific transcription of Csf1r and reporter gene expression has been
reviewed elsewhere.1,20 An inducible Fas-based suicide gene driven by
the Csf1r promoter (the so-called MAFIA mouse) has been applied to
functional studies of M𝜙s in vivo without evidence of ectopic expres-
sion or adverse impacts on other cell types.43
In spite of this compelling evidence that Csf1r expression is
restricted to cells of the monocyte/M𝜙 lineage, the recent studies of
the CSF1R homozygous mutation in human patients25,26 and reviews
of CSF1R roles in embryonic and postnatal development (e.g., ref. 44)
cite a small number of studies that claim to demonstrate expression
of Csf1r in non-hematopoietic cells including neuronal progenitors,
intestinal and renal epithelial cells, and cells of the female reproduc-
tive system. If these reports are correct, then some of the pleiotropic
impacts of CSF1R mutations in patients and experimental animals
might be attributed to defects in non-myeloid cells. It is therefore
timely to re-evaluate the evidence from these reports for non-myeloid
expression of CSF1R.
There are several caveats to each of the studies claiming func-
tional expression of CSF1R outside the mononuclear phagocyte lin-
eage, notably in relation to the specificity of anti-CSF1R Abs. In the
mouse brain, Sierra et al.45 provided detailed evidence that the Csf1r-
EGFP reporter gene produced by our laboratory32 is restricted in its
expression to microglia and perivascular M𝜙s at all stages of post-
natal development and in injury and ageing models. Using additional
Csf1r reporter genes in mice and distinct anti-CSF1R Abs, we31–33 and
others46,47 have shown that expression of the transgene and CSF1R
protein is restricted to microglia and M𝜙s at all stages of brain devel-
opment. By contrast, Nandi et al.48 reported that Csf1r mRNA was
expressed in neuronal progenitors and used Ab staining to demon-
strate high levels of expression of CSF1R protein in these cells in the
early postnatal period. The specificity of their Ab binding was based
upon lack of binding to Csf1r−/− mouse brains, but curiously, the Ab
did not appear to detectmicroglia inwild-typemice. Their studywould
suggest quite high levels ofCsf1rmRNA in the developingmouse brain.
This is clearly not evident from analysis of deep RNAseq data, includ-
ing the time course of embryonic development41 in which expres-
sion is low and tightly correlated with increased expression of other
known M𝜙-specific transcripts. In detailed network analysis of the
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transcriptomes of isolated cells from mouse and human brain, Csf1r is
clearly part of a microglia-M𝜙 signature.49,50
Based upon conditional deletion of Csf1r with a Nestin-cre trans-
gene and direct impacts of added CSF1 or IL-34 to “microglia-free”
forebrain cultures (selected based upon Nestin-EGFP expression),
Nandi et al.48 proposed that CSF1 acts directly on neuronal stem
cells. The interpretation of these studies depends on the view that
the Nestin promoter is not active in microglia. However, Nestin mRNA
is detectable in isolated microglia at levels higher than total brain
(see data in ref. 13 and www.biogps.org). A subsequent study51 also
used Nestin-cre to provide evidence that following depletion with a
CSF1R kinase inhibitor (see below)microglia repopulate from aNestin-
expressing progenitor. The transient expression of Nestin in microglia
self-renewing following ablation was confirmed by another group
using a different model.52
The most widely cited study claiming neuronal expression of
Csf1r53 investigated the potential of CSF1R ligands as treatment for
dementia and claimed that systemic administration of CSF1 or IL-34
could ameliorate neurotoxicity associated with excitotoxic injury. The
authors were not able to detect specific staining for CSF1R protein in
wild-type brain that was absent in Csf1r−/– mice using any of 6 com-
mercially available polyclonal anti-mouse CSF1R Abs. However, based
upon in situ hybridization, they reported expression of Csf1r mRNA
in scattered neurons in normal uninjured mouse brain, notably in the
neuron-dense hippocampal pyramidal layers, and an apparent increase
in labeled cells in this region following kainic acid-induced injury.
The underlying assumption was that there are no microglia among
the neuronal cells. Using an amplified Csf1r-ECFP reporter gene, we
detect positive cells in the same regions, but they clearly resemble
microglia (Fig. 1A). Both this transgene and our Csf1r-EGFP and Csf1r-
mApple transgenes are stringently restricted to CD45+ hematopoietic
cells in digests of brain, and within that set, co-expressed with the
myeloid marker CD11b.31–33 The study by Luo et al.53 used 2 other
Csf1r reporter gene systems; the MAFIA mouse (which has an EGFP
reporter separated by an internal ribosomal re-entry site43) and a
conditional Csf1r-Cre-dependent EGFP reporter, to demonstrate
apparent induction of Csf1r in injured neurons. They detected EGFP
by Ab staining rather than direct imaging of EGFP fluorescence, so
even if the signal reflects some level of inducible promoter activity, the
signal is not quantitative. Finally, Luo et al.53 generated a conditional
knockout by crossing a floxed allele of Csf1r to CaMKIIA-cre to delete
the Csf1r gene in neurons. These mice were reported to be more
susceptible to kainic acid injury. But the controls in this caseweremice
that lacked the CaMKIIa-cre transgene. There is a need for caution
in interpreting both this result and those obtained with Nestin-cre.
High-level expression of cre recombinase can clearly have impacts
on cellular function.54 It is entirely possible that expression of cre in
neurons directly impacts their functions including the production of
CSF1 and IL-34 and the sensitivity to toxic challenge. In overview, we
consider there is compelling evidence for the exclusive expression of
Csf1rmRNA and CSF1R protein in the brain in microglia andM𝜙s.
In the intestine, in Csf1op/op and Csf1r−/− mice, Paneth cells were
lost and there was disordered differentiation of epithelia including
an excess of goblet cells.55–57 In the mouse, Csf1r was apparently
expressed functionally by Paneth cells and by other epithelial cells in
both small and large intestine based upon staining with a commercial
rabbit polyclonal Ab against CSF1R.55–57 Conditional deletion of Csf1r
with a tamoxifen-inducible Villin-cre reproduced intestinal epithelial
disruptions associated with Csf1r mutation leading to the conclusion
that Csf1r function is intrinsic to epithelial cells.55 Consistent with the
cautionary note above about cre recombinase, Bohin et al.58 subse-
quently showed that tamoxifen-inducible Villin-cre activation per se
led toDNAdamage and cleavage of cryptic LoxP sites in intestinal stem
cells. A secondary concern with the inducible cre recombinase system
is that tamoxifen is not aneutral agonist, especiallywhenapplied toM𝜙
biology (reviewed in ref. 1). The role of Csf1r in intestinal homeostasis
was reinvestigated inour groupbyexploring the impact of treatmentof
micewith a purified blocking ratmAbagainstmouseCSF1R. Prolonged
treatment completely depleted lamina propriaM𝜙s and also disrupted
epithelial differentiation leading to increased goblet cells and the loss
ofmicrofold (M) cells.59 However,we did not reproduce the expression
of Csf1r in epithelial cells. Instead, we demonstrated that the expres-
sion of both Csf1r mRNA and Csf1r-EGFP expression was completely
restricted to lamina propria M𝜙s. Figure 1B shows the intimate asso-
ciation between crypt-associated M𝜙s and intestinal stem cells. This
conclusion was supported by mRNA analysis of isolated intestinal cell
populations. Furthermore, conditional deletion of Csf1r using a consti-
tutive Villin-cre had no effect on epithelial differentiation. Importantly,
Paneth cells were not actually depleted by anti-CSF1R; their expres-
sion ofmarkers such as lysozyme anddefensinswas lost indicating that
M𝜙s control their differentiation rather than their survival.59 In the
rat, we also saw no effect of the Csf1r null mutation on the presence of
Paneth cells or onoverall villus architecture.40 Wehavenot yet investi-
gatedwhether epithelial function is regulatedby interactionswithM𝜙s
in this species.
Resident M𝜙s are an abundant interstitial population in the kid-
ney and Menke et al.60 claimed that CSF1 signals directly to renal
tubular epithelial cells to promote repair of hypoxic injury. Inducible
expression of Csf1 in damaged tubular epithelial cells has been repro-
duced by multiple authors. Exogenous CSF1 administration promoted
epithelial repair and anti-CSF1R treatment, CSF1R kinase inhibition
or genetic deletion of Csf1 increased the pathology or delayed reso-
lution in several different injury models.60–63 Menke et al.60 claimed
thatCSF1Rprotein andCsf1rmRNAweredetectable in isolatedmouse
renal epithelial cells and Zhang et al.63 appeared to detect phosphory-
lated CSF1R in damaged renal epithelium using anti-CSF1R Ab. In the
former study, protein detection was based upon the same rabbit anti-
mouse CSF1R preparation used by Nandi et al.48 The authors noted
that Csf1r mRNA expression was considerably lower than in M𝜙s and
contamination byM𝜙s was not excluded. Based upon conditional dele-
tion using an Itgam-diptheria toxin receptor transgene, Menke et al.60
argued that M𝜙s make a minor contribution to CSF1-dependent
repair. Our own study in a similar renal ischemia model, which repro-
duced the beneficial effect of CSF1 treatment, strongly favors the
M𝜙 as the mediator of tissue repair and the exclusive responder to
CSF1 administration.61 This conclusion is supported by subsequent



















F IGURE 1 ExpressionofCsf1r reporter genes is restricted tomacrophages.Panel (A) showsexpressionof cyan fluorescentprotein inmicroglia
in the hippocampus of the brain of MacBlue (Csf1r-GAL4VP16/UAS-ECP) mice. The neuronal cells of the pyramidal layer are stained for the neu-
ronal marker NeuN. Reproduced from ref. 33 with permission. In the same study, both ECFP and Csf1r-EGFPwere detected in disaggregated total
brain by FACS exclusively in cells that co-expressedCD11b. Panel (B) shows an optical section of a 3Dwholemount of the crypt of a small intestinal
villus of Csf1r-EGFP mice, stained for the Paneth cell marker, lysozyme. Note the intimate association between EGFP+ cells and the basal mem-
branes of epithelial cells. Phalloidin staining of F-actin is used as a counterstain and highlights the basolateral and apical regions of epithelial cells
and the non-M𝜙 cells (including endothelial cells and fibroblasts) in the lamina propria. Reproduced andmodified from ref. 59 with permission and
thanks to Dr. A Sehgal
studies.62,63 Menke et al.60 described an apparent increase in Csf1r-
EGFPexpression in epithelial cells in response to renal injury but in our
view, the apparent increase in EGFP fluorescence was attributable to
M𝜙 infiltration of the damaged epithelial layers and autofluorescence
of tubular casts.61 In neither study was there any evidence of expres-
sion of the Csf1r-EGFP reporter genes in undamaged renal epithe-
lium consistent with the original description of the transgene.31,32
As in the brain, the increasing abundance of Csf1r mRNA in the kid-
ney during embryonic and postnatal development correlated closely
with other M𝜙 markers.41 In summary, the claim that CSF1 signals
directly to renal tubular epithelial cells in any circumstance is not
strongly supported.
There are high-affinity mAbs against murine CSF1R that detect
expression in isolated monocytes and progenitors (e.g., ref. 60 and
64) but they have not been used successfully to detect the protein
in tissues. In fact, it is intrinsically unlikely that the CSF1R protein is
detectable at high levels in tissues because it turns over constantly
upon ligand binding (see below). As an alternative, we developed an
AF647-conjugated version of CSF1. This protein bound specifically to
monocytes isolated from the blood of mice and rats and when injected
intomice localized specifically to tissueM𝜙s.31,40,65
The restriction of CSF1R expression to M𝜙s and microglia is also
supported by studies using Csf1r kinase inhibitors. Elmore et al.51
reported the almost complete elimination of microglia from themouse
brain using selectiveCSF1R inhibitors. Therewas no evidence of a phe-
notypic impact and gene expression profiling revealed only the loss of
known microglia-associated transcripts. Since this original report, the
inhibitor PLX3397 has been used extensively in studies of the func-
tions of microglia in brain and retinal development and homeostasis
(e.g. ref. 66–69, and references therein)without anyevidenceof effects
on non-myeloid cells. The lack of effect is actually surprising. Contrary
to the way it is portrayed explicitly in many publications, PLX3397 is
not a specific CSF1R kinase inhibitor; it is also an effective inhibitor
of related kinases KIT and FLT370–72 and likely mediates its effects
on microglia in part by interacting with other kinase targets. Another
orally available CSF1R kinase inhibitor, GW2580, also penetrates the
brain but unlike PLX3397, it prevents microglial proliferation/self-
renewal without impacting on survival.46
Taking all of these data together, we believe there is no reason to
consider Csf1r expression outside of myeloid lineages in the interpre-
tation of mutant phenotypes in experimental animals or humans.
1.2 CSF1R signal transduction
The binding of CSF1 or IL34 to CSF1R and the downstream signal-
ing events have been reviewed in detail by Stanley and Chitu.73 CSF1
signal transduction has mostly been studied in mature M𝜙s, osteo-
clasts, or cell lines, and mainly in mouse systems where CSF1 is not
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produced byM𝜙s themselves and endogenous/autocrine CSF1 signal-
ing is therefore not an issue. For obvious reasons, the CSF1 response is
also commonly studied in cells that have been deprived of growth fac-
tor to allow up-regulation of surface receptor and the analysis of a syn-
chronous response to receptor ligation.
In broad outline, studies of CSF1 signaling have shown that ligand
binding induces dimerization of the receptor and release of the kinase
domain from an auto-inhibited conformation leading to initial tyrosine
phosphorylation and ubiquitination of a membrane proximal domain.
Trans-phosphorylation of individual tyrosine residues in the intracel-
lular domain then provides a scaffold for recruitment of several dif-
ferent effector pathways linked separately to survival, increased cell
motility, proliferation, and specific gene regulation. One of these path-
ways is the classical SOS-GRB2-RAS-RAF-MAPK pathway that was
first dissected in detail in the analysis of “sevenless/pointed” pathway
in Drosophila.74 The same pathway from CSF1R through SOS/GRB2,
RAS, RAF, and the MAP kinases ERK1/ ERK2 leads in M𝜙s to phos-
phorylation of the transcription factor ETS2 on the pointed domain.
ETS2 then interacts with AP1 transcription factors on a conserved Ras
response element to activate transcription of urokinase plasminogen
activator (Plau)75–78 in the same way that AP1 (Jun) interacts with
pointed to induce photoreceptors in the Drosophila eye.79
Following initial signal generation, the SOS-GRB2 complex dis-
sociates from the receptor, there is further tyrosine and serine
phosphorylation and a cascade of ubiquitination culminating in degra-
dation of both ligand and receptor in lysosomes.73 Internalization and
degradation of the receptor is not blocked by inhibitors of receptor
kinase activity.80 Further signaling, therefore, requires continuous
synthesis of new receptors on the cell surface. The nature of the
response to CSF1 depends upon the duration and magnitude of that
continued stimulation. Removal of CSF1 from bone marrow-derived
M𝜙s (BMDM) at any time leads to rapid loss of expression of Plau
mRNA81 and CSF1 must be present continuously in order for cells to
enter S phase and subsequently undergo cell division. Because CSF1 is
internalized and degraded, binding at 37◦C is irreversible and ligand is
depleted from the medium. The degradation of CSF1 by proliferating
mouse bone marrow-derived M𝜙s is saturated at concentrations that
are required to drive entry into the S phase if the cell cycle.9 As a
consequence of the rapid degradation of the ligand, the dose-response
curve for CSF1 action on any measured outcome in cell culture is
very steep.82 It is actually not a concentration dependence, but a
titration of the amount of CSF1 available per cell per hour. If the cells
exhaust the supply of growth factor at any time, the signaling cascade
terminates. For example, the CSF1-dependent phosphorylation of
the MAP kinases ERK1/ERK2 and of their target ETS2 in M𝜙s is
sustained for as long as CSF1 is present.75 The outcome of signaling
also depends upon the cell population. Mature peritoneal M𝜙s are
more effective at internalization and degradation of CSF1 thanBMDM
but do not undergo proliferation; they can compete in vitro for the
available CSF1.82,83 The M𝜙s of the liver clear CSF1 from the blood84
thereby maintaining a low circulating concentration (∼20 ng/ml39)
that is less than saturating for M𝜙-mediated clearance by the
receptor (∼70–100 ng/ml).
The circulating CSF1 concentration in vivo is also sub-stimulatory
formonocyte production by the bonemarrowand for proliferation and
regulated gene expression in resident tissue M𝜙s. As a consequence,
the entire mononuclear phagocyte system can respond to increased
CSF1 availability. Administration of CSF185 or a CSF1-Fc fusion pro-
tein (which has a longer circulating half-life7,31,86,87) leads to both
expansion of the blood monocyte pool and proliferation of resident
M𝜙s in all organs. It also induces expression by M𝜙s of Plau and other
target genes with similar regulatory elements (e.g., Mmp9). A striking
and unexpected consequence of CSF1-Fc treatment is extensive hepa-
tocyte proliferation leading to a rapid expansion of the size of the liver
inmice, rats, andpigs.34,86,87 This finding indicates thatM𝜙s contribute
to the homeostatic regulation of liver size relative to body size.86 Res-
ident M𝜙s have relatively low rates of proliferation/self-renewal as
noted in the original descriptions of the mononuclear phagocyte sys-
tem (reviewed in refs. 1 and2).Nevertheless, liverM𝜙s, andmost other
tissueM𝜙 populations do require CSF1R signals for continued survival
and in mice, they are rapidly and sustainably depleted in response to
anti-CSF1R treatment.64,88
Like all signaling pathways, CSF1R signaling at multiple levels is
subject to feedback controls, many of which are themselves CSF1-
inducible (reviewed in ref. 73). They include protein tyrosine phos-
phatases, serine phosphatases, dual-specificity phosphatases (DUSP),
inositol phosphatases, and suppressors of cytokine signaling. Deficien-
cies in any of these feedback mechanisms can lead to uncontrolled
CSF1R signaling and each of them is therefore a potential epistatic
modifier of the effect of CSF1R mutations. For example, mutation of
the SHP1 hematopoietic tyrosine phosphatase (encoded by Ptpn6)
in the motheaten mouse leads to constitutive activation of ERK1/2-
dependent ETS2 phosphorylation and expression of CSF1R target
genes such as Plau inM𝜙s and factor-independent survival.89 As a con-
sequence of the separation of internalization and degradation from
kinase activity and the presence of so many feedback pathways the
efficiency of signaling can be controlled at multiple levels. For exam-
ple, an old study showed that glucocorticoids actually shift the CSF1
dose-response curve for induction of Plau and proliferation in mouse
BMDM so that cells consume and degrade more CSF1 to produce the
same outcome.83 One of the conserved actions of glucocorticoids in
mouse and humanM𝜙s is to induce the expression of theMAPKkinase
inhibitor DUSP1,90 which would act to reduce the effective activation
of ERK1/2 and efficiency of downstream transmission of the CSF1R
signal. The CSF1R/glucocorticoid axis may also be relevant to under-
standing variable penetrance of CSF1Rmutant phenotypes.
1.3 The phenotypes associatedwith CSF1, IL34,
and CSF1Rmutations inmice
Most of our current knowledge of mononuclear phagocyte adaptation
is derived from studies of inbred mice. In terms of M𝜙-specific and
inducible gene expression, mouse and human M𝜙s are substantively
different from each other.8,90 Recent comparative analysis of mouse
and human microglial expression signatures also revealed significant
differences in gene expression driven by species-specific variation
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TABLE 1 Summary of mutations of Csf1r, Csf1, and Il34 in rodents
Gene/species Genetic background Survival References
Csf1op/op mouse Mixed B6/C3H Adult, bone phenotype resolves with age 39,92–95
Csf1op/op mouse Inbred C57BL/6 Lethal 106
Csf1fl/fl x Cre Inbred C57Bl/6 Osteopetrosis 157
Csf1tl/tl rat Inbred Fischer Adult, no resolutionwith age 119
Csf1r−/− mouse Mixed 129/Sv and B6/C3H >80 days, bone phenotype resolves with age 39
Csf1r−/− mouse Inbred C57BL/6 Few survive to wean 106
Csf1r−/− mouse Mixed FVB/NJ <4weeks 47
Csf1rdex5/dex5 mouse Inbred C57BL/6 Few survive to wean 47,102
Csf1r−/− rat Mixed DA/SD >12weeks 40
Csf1r−/− rat Inbred DA ∼12weeks Unpublished
Csf1r−/− rat Outbred SD >12weeks Unpublished
IL34LacZ/LacZ mouse Inbred C57BL/6 Adult, fertile 110
in cis-regulatory elements and transcriptional regulators.91 Nev-
ertheless, the biology of CSF1R is conserved in mammals and the
mutations in rodents have provided clear insights intoM𝜙 functions in
development. Table 1 summarizes the mutations that have been
studied in laboratory animals and the impacts of genetic background.
The osteopetrotic mouse is a spontaneous mutation first described
in detail by Marks and Lane.92 The original characterization included
a failure of tooth eruption, excessive accumulations of bone and
compromised marrow cavities, increases in bone matrix formation,
and hypophosphatemia associated with primary deficiency of bone-
resorbing osteoclasts. Subsequently, 2 groups identified an inactivat-
ing mutation of Csf1 (a single base insertion before codon 88, which
results in a premature stop codon after 21 bases) in these mice, now
referred to as Csf1op/op.93,94 The original description of the Csf1op/op
mouse noted that the osteoclast deficiency and reduction in bonemar-
row cellularity resolves with age and extramedullary hematopoiesis
in the spleen is corrected.95 In the spleen of mutant mice, there is
a substantial expansion of committed M𝜙 progenitors,95 but CSF2
(GM-CSF), which can also act upon these shared progenitors, was
not required for age-dependent correction.96 Age-dependent reso-
lution of the Csf1op/op bone phenotype has been attributed to sig-
nals from other tyrosine kinase receptors/ligands notably VEGFA and
FLT3L.97,98 Csf1op/op mutation in mice also leads to reduced M𝜙 num-
bers in most organs99 and there are numerous pleiotropic impacts
including compromisedpostnatal growth, extensive skeletal abnormal-
ities, defects in sensory neuronal systems, abnormal intestinal orga-
nization, Paneth cell deficiency, relative male and female infertility,
delayed beta cell development in the pancreatic islets, reduced mam-
mary gland development, defective angiogenesis and lymphangiogen-
esis, partial B cell deficiency, and altered neurogenesis and brain devel-
opment (reviewed in refs. 44 and 100). Among many applications,
Csf1op/op mice have been used to infer the role of CSF1-dependent
M𝜙s in the control of cholesterol metabolism and the development of
atherosclerosis (reviewed in ref. 101).
Targeted mutation of the Csf1r locus in mice by insertion of a
reporter gene within exon 339 revealed a very similar phenotype to
the Csf1op/op including an expansion of committed M𝜙 progenitors
in the spleen. As in the case of the ligand mutation, the bone mar-
row cellularity and osteoclast deficiency resolvedwith age. In this orig-
inal study, the Csf1r mutation was generated on the inbred 129SvJ
genetic background and crossed to the Csf1op/op line on a mixed
C57BL6/C3Heb/FeJ genetic background on which the mutation is
maintained by the Jackson Laboratories to enable comparison of sin-
gle and double mutations. With this complex cross, the majority of
single or double homozygous Csf1r−/− and Csf1op/op mice survived to
adulthood (at least 80 days). The phenotypic impacts of the 2 muta-
tions were not additive because the double homozygote phenotype
was largely indistinguishable from either single homozygote. Both
receptor and ligand mutant animals were reportedly able to gen-
erate progeny, albeit their fertility was greatly compromised. Small
differences in bone phenotype and marginally greater pre-weaning
mortality in Csf1r −/- mice provided some indication of the exis-
tence of a second Csf1r ligand. Unfortunately, the original study of
the mutation on the mixed genetic background did not examine the
brain. Based upon subsequent studies, the Csf1r −/– mice that sur-
vived beyond weaning were presumably microglia-deficient but not
severely affected.
Most subsequent studies of Csf1r mutant mice, including a sec-
ond conditional mutation (deletion of exon 5) made by another
laboratory102 have been carried out on 1 of 2 inbred genetic back-
grounds (FVB, C57BL/6) where the perinatal lethality is much more
penetrant and very few mice survive to weaning.44 In a subsequent
study, Dai et al.103 examined the bone phenotype of juvenile Csf1r-/-
mice on an inbred background (FVB/NJ) in greater detail. These mice
died within the first 4 weeks of life. In juvenile mutants, they observed
chondrodysplasia and defects in collagen matrix organisztion and
mineralization and defects in osteoblasts. Using a novel approach, they
transplanted fetal femoral anlagen from Csf1r−/- mice into wild-type
mice and showed that infiltrating recipient osteoclasts permitted the
generation of normal cortical bone in the transplanted tissue. Although
these authors suggested that M𝜙s were not involved in resolution
of the bone osteoblast function in this model, subsequent studies of
the control of osteoblast calcification104,105 indicate that the loss of
M𝜙s associated with the bone surface probably also contributes to
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any bone phenotype. Interestingly, Chitu et al.106 reported that the
Csf1op/op is also lethal on a different inbred background (C57BL/6),
where more survive on the FVB background and 60–80% of mutant
mice survive to weaning on the original mixed genetic background.
Another group107 studied a more limited backcross of the Csf1op/op
to this genetic background and found that the homozygotes could
be maintained to adulthood with careful husbandry and feeding.
The idiosyncrasies of C57Bl/6 mice as a model for M𝜙 biology have
been reviewed elsewhere.1 One relevant feature is that they have an
intrinsically low bone density. Female C57BL/6 develop spontaneous
osteoporosis at a relatively young age, and this can be blocked by anti-
CSF1R treatment.88 If anything, the ligand mutation in C57BL/6 mice
is more severe than the receptor mutation. Curiously, heterozygous
mutation of Csf1r abolished the pre-weaning mortality of the Csf1op/op
mutation.39 There is a similar paradox in the case of Flt3, which
encodes a receptor tyrosine kinase (FLT3) related to CSF1R. FLT3 and
CSF1R are both present on the cell surface of a shared bone marrow
progenitor of themonocyte-dendritic cell lineage inmice.108 Mutation
of the ligand gene (Flt3l) has an even greater impact than mutation of
the receptor gene (Flt3) on dendritic cell maturation. Durai et al.109
proposed that FLT3 is retained on the cell surface in the absence
of FLT3L and effectively cross-competes for signaling molecules on
progenitor cells with CSF1R. On the other hand, the absence of FLT3
permits increased CSF1R signaling and partial rescue of the dendritic
cell deficiency. The potential cross-talk between tyrosine kinase
receptors may be relevant to mutant CSF1R phenotypes and variable
penetrance in humans discussed below.
Leaving aside whether the differences in apparent severity of
ligand and receptor mutations are dependent on genetic background,
another explanation for any increased severity of the Csf1r mutation
relative to the Csf1op/op was provided by the identification of the
second ligand, IL-34. The knockout of the mouse Il34 gene (removal
of Exons 3–5; inbred C57BL/6 background) revealed a substantial but
incomplete depletion of microglia in the brain and loss of Langerhans
cells in the skin.110 IL-34 activation of Csf1r appears functionally
equivalent to CSF1 in that transgenic expression of Il34 under the
control of the Csf1 promoter rescued the phenotypes of the Csf1op/op
mouse (at least on an inbred FVB/NJ background).111 The impact of
the Il34 mutation is consistent with the major sites of expression of
Il34 in both mice and humans.13 Within the mouse brain, Il34 and
Csf1 have distinct and largely non-overlapping distributions across
regions, and the knockouts of the 2 ligands accordingly show distinct
impacts on regional microglial densities.106 Studies in vitro do not
support the idea that CSF1 and IL-34 have any differential signaling
effects on microglia.112 A second receptor for IL-34, PTPRZ, has been
identified113 but thus far no phenotype has been described in the
mouse Il34 knockout that is incompatible with effects solely mediated
by CSF1R. Recent studies have extended the analysis of differential
Il34 dependency to distinct niches in the retina114 and to M𝜙s of the
kidney.115 By contrast to mice, extensive profiling of human brain
regions in the FANTOM5 project did not indicate a significant excess
of IL34 over CSF1 mRNA, nor any region specificity.13 However, the
transcriptomic data do identify separate promoters/transcription
start sites associated with expression of IL34 in skin and brain in both
mouse and human.
As discussed above, some impacts of Csf1r mutations on the brain
have also been attributed to direct actions on neuronal cells.48 Erblich
et al.47 on the other hand, demonstrated clearly that Csf1r mRNA
and protein and Csf1r reporter genes were expressed exclusively in
microglia. They described in detail the progressive postnatal enlarge-
ment of the lateral ventricles in Csf1r−/− mice on the C57BL/6N back-
ground and argued that many of the impacts of the mutation may
be secondary to severe hydrocephalus. Consistent with this view,
and further highlighting the impact of genetic background, mutations
in the genes encoding the junctional adhesion molecule JAM3 and
the FYN kinase also produce severe hydrocephalus when crossed to
the C57BL/6 background with phenotypic consequences in the brain
parenchyma resembling the Csf1r knockout.116,117
1.4 The rat as an alternative rodentmodel of
Csf1r deficiency
Therehavebeenconsiderably fewer studiesofCSF1Rsignalingbiology
in the rat. The toothless rat (Csf1tl/tl) has a frame-shift mutation in the
Csf1 gene that ablates function.118,119 Most studies of the Csf1tl/tl rat
have focused on the bone phenotype and the control of tooth eruption.
By contrast to the Csf1op/op mouse, which retains some osteoclasts
and recovers with age, the Csf1tl/tl rat has an almost complete loss
of osteoclasts, chondrodysplasia and unremitting osteopetrosis that
was only partly overcome by postnatal CSF1 administration.119–124
Like Csf1op/op and Csf1r−/− mice, Csf1tl/tl rats also exhibited severe
postnatal growth retardation, which was associated with deficien-
cies in the growth-hormone/IGF1 axis.123,125 We recently generated
a Csf1r knockout rat by homologous recombination in embryonic stem
cells.40 Like the Csf1op/op mice, these rats had a complete deficiency
of osteoclasts and also lacked bone-associated M𝜙s (osteomacs) that
are required for osteoblast maintenance and both endochondral and
intramembranous ossification.104,105 Despite the lack of osteoclasts,
the bone phenotype of mutant rats was distinct from the mouse with
much greater preservation of a marrow cavity and no evidence of
extramedullary hematopoiesis in the spleen. Unlike Csf1r−/− inbred
mice, the large majority of mutant rats survived beyond weaning.
Figure 2 shows a comparison of the skeletal phenotypes of adult wild-
type andmutant rats.
Analysis of female Csf1r−/− rats at 11–12 weeks revealed complete
loss of specific M𝜙 populations, including microglia, Langerhans cells,
splenic marginal zone M𝜙s, and peritoneal M𝜙s whereas other M𝜙
populations were partly CSF1R-independent. Both sexes are likely to
be infertile. The gonads and secondary sexual organs were poorly-
developed in both males and females and the differential growth of
males versus females was abolished. One phenotype of the Csf1r−/−
rats, which was not observed in mutant mice, was the complete loss of
visceral adipose tissue. Despite the complete absence of microglia in
Csf1r−/− rats, there was limited evidence of brain pathology aside from
mildly enlarged lateral ventricles, thinning of the corpus callosum, and
altered differentiation of dopaminergic neurons. Expression profiling
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F IGURE 2 The effect of Csf1r mutation in rats on skeletal devel-
opment. The X-ray image compares the skeletal development of an
11-week-old female Csf1r−/− rat with a control wild-type littermate.40
Note in particular the increased calcification of the skull base (arrows),
a phenotype sharedwithpatientswithhomozygousCSF1Rmutation.25
There is also an overall reduction in body size and increased calcifica-
tion of the long bones (especially the hind limbs) and the entire verte-
bral column, also a feature of the human syndrome25
of several brain regions (hippocampus, olfactory bulb, striatum, pitu-
itary) revealed the selective loss of many known microglia-associated
transcripts. However, there was no effect on expression of genes asso-
ciated with neuronal progenitors (e.g., Dcx, Cux1); thus providing no
support for a non-redundant functional role for Csf1r in growth or sur-
vival of neuronal progenitor cells.
Since this original study, where the linewas an early backcross to an
inbred line, we have bred the rat Csf1r knockout fully to a fully inbred
dark agouti and a fully outbred (Sprague-Dawley) genetic background.
On the pure inbred background, survival toweaning is somewhatmore
compromised and we see more severe ventricular enlargement in the
brain and almost complete loss of the olfactory bulbs similar to the
Csf1r-/− mouse at 3weeks47,48 but in older adult animals (11-12weeks,
unpublished). Regardless of genetic background, the Csf1r−/− rats do
not exhibit sensory neuronal defects (unlike Csf1–/− and Csf1op/op
mice,39 they are not deaf) nor the loss of Paneth cells in the gut, as
reported inmutant mice.
1.5 Growth deficiency in CSF1R-deficient animals
Mutations of Csf1r in both mice39 and rats40 lead to reduced body
weight. The growth retardation in Csf1tl/tl rats was reportedly
associatedwith an almost complete loss of circulating IGF1.123,125 The
Csf1r−/− rats were indistinguishable from litter mates at birth but in
common with Csf1tl/tl rats, their growth rate declined rapidly.40 The
impacts of Csf1r mutations have some obvious similarities to growth
hormone (GH)/IGF1 mutations (reviewed in ref. 126). Like Csf1r−/−
animals, GH-deficient (Ghlit/lit) or GH receptor-deficient (Ghr−/−) mice
are born normal size and the growth defect manifests from around
2 weeks of age. Igf1 deficiency has a greater impact on embryonic
growth thanGh orGhrmutation but as is the case with Csf1rmutation,
the perinatal lethality depends on genetic background.127 Although
the liver is the main source of IGF1 in the circulation, conditional
deletion of Igf1 in hepatocytes did not cause a substantial reduction in
postnatal growth.126 MouseM𝜙s grown inCSF1 also express very high
levels of Igf1mRNA initiated from a separate promoter from that used
in the liver.125 Chitu and Stanley44 have argued that the growth defi-
ciency inCsf1orCsf1rmutant animals is secondary to thebone/skeletal
abnormality; essentially a consequence of osteoclast deficiency. They
noted that transgenic expression of human CSF1 in mouse bone from
an osteoblast-specific promoter was able to overcome the growth
and skeletal defects in Csf1op/op mice.128 This finding does not argue
against a central role for CSF1 in growth control since CSF1 was
also elevated in plasma in these transgenic mice and the impact on
circulating IGF1 was not measured. Chang et al.129 confirmed the
high expression of Igf1 mRNA in inflammatory M𝜙s in adipose tissue,
but conditional deletion of Igf1 in myeloid cells using LysM-cre did not
produce a change in circulating IGF1, growth, or body composition.
However, LysM-cre does not produce efficient recombination in most
resident tissue M𝜙 populations (see ref. 130). Expression profiling of
the liver of Csf1r−/− rats revealed a relatively small reduction in Ghr
and Igf1, probably insufficient to explain the growth retardation40
and suggesting there is not a primary GH deficiency. There are many
other possible axes of regulation that might explain the loss of control
of circulating IGF1 by CSF1R-dependent M𝜙s. IGF1 has a very short
plasma half-life unless bound bymembers of the IGFBP family. Altered
expression of these proteins in liver or in other tissues, or changes in
their posttranslational modification, could lead to indirect impacts on
circulating IGF1.131 Additionally, recent studies have shown that IGF1
is generated in muscle as a pro-IGF1 form that requires processing.132
Conditional deletion ofmuscle-specific Igf1 expression can also reduce
circulating IGF1 and impair somatic growth133 whereasM𝜙-expressed
Igf1 appears essential for muscle regeneration following injury.134
As well as contributing directly as a source of IGF1 production, M𝜙s
are obvious candidates for a role in proteolytic processing of both
pro-IGF1 and IGFBPs. Whereas the precise mechanism is unclear and
probably complex, CSF1R mutation clearly impacts the GH-IGF1 axis
and many of the pleiotropic consequences in rodents are probably
linked to that impact.
1.6 A hypomorphic Csf1rmutation inmice
The transcriptional regulation of the Csf1r gene has been analyzed in
detail in both mice and humans (reviewed in ref. 20). The major M𝜙-
specific transcription start site region contains multiple binding sites
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for theM𝜙-expressed transcription factor, PU.1. The expression of the
Csf1r reporter genes in M𝜙s in transgenic mice depends upon a highly
conserved intronic enhancer element (FIRE).32 To test the function of
FIRE in its normal genomic context, we deleted the 300 bp sequence
from the mouse germ line to produce Csf1rΔFIRE/ΔFIRE mice.135 Given
the level of conservation, we anticipated a phenocopy of the Csf1r
knockout. Instead, we found a selective loss of certain tissue M𝜙 pop-
ulations, notably complete absence of microglia, Langerhans cells of
the epidermis, and heart, kidney, and peritoneal M𝜙s. However, most
major M𝜙 populations expressed Csf1r normally and/or were unaf-
fected in Csf1rΔFIRE/ΔFIRE mice; the animals have normal bones, grow
normally, and are fertile. Furthermore, the mutation distinguishes
the brain-associated and perivascular M𝜙 populations,136,137 which
were retained despite their complete loss of Csf1r expression, from
the microglia, which were lost. Despite the complete loss of microglia,
and of Csf1r mRNA and other microglial markers in the brain, there
was no apparent brain phenotype in Csf1rΔFIRE/ΔFIRE mice and no
detectable change in expression of any genes that are not clearly
myeloid-associated. These mice, along with the Csf1r null mutation on
outbred genetic backgrounds inmice and rats, tell us that the functions
of microglia in development are largely redundant. The elimination
of microglia in adults has no obvious pathological impact and seems
to protect against several forms of brain injury.68,138,139 Similarly, the
microglial deficiency in Il34mutant mice (∼80% in most brain regions)
has no apparent phenotypic consequences in the steady state but does
compromise the ability of mice to deal with pathology associated with
viral infection of the brain.110 These findings support the view that
the effects of Csf1r deletion on the brain may be attributable in part
to the primary hydrocephalus, which does not occur in Csf1rΔFIRE/ΔFIRE
or the Il34−/– mice and is greatly delayed in Csf1r−/− rats. The effects
of Csf1r inhibitors such as PLX339751 discussed above and Csf1r
knockouts may also depend in part upon systemic effects including
the loss of circulating IGF1 described above. For example, we suspect
that impacts of the microbiome onmicroglial numbers andmaturation
depend indirectly upon peripheral CSF1 deficiency and consequent
changes in peripheralM𝜙 populations.140,141
1.7 What do the rodentmodels tell us about the
impact of human CSF1Rmutations?
ALSP is an adult-onset degenerative disease of the brain leading to
multiple cognitive, behavioral, and motor dysfunctions.22,23 The histo-
logical hallmark of the disease is white matter destruction leading to
the loss of axons andmyelin, thinning of the corpus callosum, calcifica-
tion, axonal swellings (‘spheroids’), and the accumulation of pigmented
M𝜙s. The point mutations in CSF1R associated with ALSP (reviewed
in refs. 22 and 23, and annotated in Ensembl) are concentrated in the
intracellular tyrosine kinase domain. The entire intracellular domain
of CSF1R is highly conserved across vertebrate species and even
the chicken CSF1R can signal to support proliferation and differen-
tiation when expressed in mammalian cells.142 Without exception
ALSP-associated mutations alter amino acids that are conserved
in the chicken receptor. We expressed CSF1R containing a range
of human mutations in the BaF3 factor-dependent cell line where
wild-type receptor can sustain CSF1-dependent proliferation.65
Whereas each of the mutant proteins was defective in signaling,
they were expressed on the cell surface at comparable levels to the
wild-type receptor, bound CSF1, and were internalized in response to
binding. In an ALSP patient heterozygous for a CSF1R point mutation
that abolishes kinase activity, we predict that 75% of receptor dimers
will be signaling defective; either homodimers of the mutant protein
(25%) or heterodimers with one mutant and one wild-type subunit
(50%). These receptor dimers will nevertheless bind and internalize
CSF1 thereby competing with the remaining 25% of functional recep-
tor dimers. As discussed above, mutant receptors may also compete
for signaling pathways with other receptors such as FLT3 that would
otherwise mitigate the impact of CSF1R deficiency. Hence, our data
support a dominant negativemodel for ALSP.
The alternative to a dominant-negative model of disease is to pro-
pose that the mutant proteins have no function and reduction of nor-
mal peptides to 50% (haploinsufficiency) is enough to cause disease.
Neither the animal models nor the human disease patients support
this proposal. In rats and mice heterozygous null mutation of Csf1r is
not dosage compensated. Monocytes andM𝜙s in blood and bonemar-
row of heterozygousmutants express half the level ofCsf1rmRNA and
protein.39,40 This is also the case in Csf1rΔFIRE/+ mice.135 In the expres-
sion profiles of the brains of heterozygous csf1r+/- rats andCsf1rΔFIRE/+
mice, there is a 50% reduction in Csf1r mRNA. Nevertheless, there is
no significant change in any other transcript in response to the 50%
loss of Csf1r.40,135 The lack of dosage compensation is rather surpris-
ing since CSF1 can induce down-regulation Csf1r mRNA in M𝜙s.143
One might have anticipated that reduced CSF1R signals would per-
mit up-regulation of expression from the wild-type allele. A further
puzzling finding is that despite the 50% reduction in Csf1r mRNA and
CSF1R protein in heterozygous mutant mice no increase in circulat-
ing CSF1 was detected.39 It seems that haploinsufficiency for Csf1r
has little impact in mice or rats and is unlikely to explain the human
dominant disease.
By contrast to the ALSP-associated mutations, the CSF1R muta-
tions described in the recessive syndromewith skeletal symptoms25,26
all appear to result in complete or partial loss of function or expres-
sion of the protein. Some lead to the generation of premature stop
codons and nonsense-mediated mRNA decay, others involve cryptic
splice acceptors leading to greatly reduced expression of thewild-type
mRNA. Heterozygous carriers are therefore “models” for genuine hap-
loinsufficiency. The recessive disease varies greatly between individ-
uals from infant mortality to adult-onset. Monies et al.144 described
a truncating null mutation (Y540*) in CSF1R in a consanguineous
family. The mutation would abolish the intracellular domain includ-
ing the kinase region and apparently led to early postnatal lethal-
ity and severe brain and skeletal phenotypes. These individuals may
be the only report of definitive human CSF1R null individuals; their
heterozygous parents and siblings were asymptomatic. Guo et al.25
reported another null mutation (Q481*) as one of the compound
heterozygous alleles in an individual with recessive skeletal dyspla-
sia and brain disorders. Similar to p.Y540*, p.Q481* would abolish
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the intracellular part of the receptor. The RT-PCR analysis for cells
derived from this patient demonstrated that mRNA from the mutant
allele is subjected to complete NMD. All the heterozygous carriers of
Q481* and Y540* in the 2 families were asymptomatic. Guo et al.25
attribute some of the variation in phenotype in the recessive disease
to the residual production of wild-type CSF1R mRNA (in the case of
splice variation) or some retained signaling function of the mutant
CSF1R encoded by one of the alleles. One disease-associated variant,
P132L, present as a compound heterozygote with the definitive loss-
of-function allele (Q481*), affects an amino acid in the domain 2 lig-
and binding domain. While this amino acid is not involved directly in
binding either CSF1 or IL3427,28 the proline is immediately adjacent to
a conserved cysteine involved in the immunoglobulin fold, and is con-
served in chickens.142 Both this mutation, and a mutation in the tyro-
sine kinase domain (K627del) that was also present as a compound
heterozygote in affected individuals, retained some biological activity
when expressed in a reporter system.25 Oosterhof et al.26 described a
family where affected individuals were homozygous for H643Qmuta-
tion in the kinase domain (also a conserved amino acid in chicken) and
heterozygous familymemberswereunaffected. They speculate that by
contrast to ALSP mutations, the H643Q mutant protein retains some
residual kinase activity. This would clearly be testable in the BaF3 cell
line system.65
A small number of studies have identified loss-of-function muta-
tions in CSF1R as the primary causal mutation in ALSP patients and
have advocated haploinsufficiency as a mechanism underlying the
disease.145–147 The proposal is supported by ALSP-like symptoms
developing in a subset of aged male heterozygous Csf1r mutant
mice on the C57BL/6 background,148 a background on which the
homozygous mutant is lethal prior to weaning. But in this model,
there was a substantial increase in microglial numbers throughout
the brain compared to wild-type mice. A detailed analysis of the
brains of multiple ALSP patients revealed the direct reverse of the
mouse phenotype.149 By contrast to other leukodystrophies, in which
microglia appear increased and activated, there were greatly reduced
microglial numbers, unevendistribution, and focal changes inmorphol-
ogy referred to as dysplasia. The loss of microglia was associated with
a marked loss of detectable CSF1R protein and the microglial marker
CD11b on Western blots in clear contrast to increased detection in
other disease states exhibiting microgliosis. In ALSP patients with
heterozygous loss-of-function mutations and a diagnosis of ALSP the
expression of the wild-type allele at the protein level in microglial
progenitors is not known. The lack of any evidence of disease in family
memberswith heterozygous complete loss of function alleles ofCSF1R
associated with the recessive disease25,26 strongly supports the view
that haploinsufficiency per se is not likely to explain the pathology
of ALSP.
Although coding variations in the intracellular domain of
CSF1R are comparatively rare, examination of the ExAC database
(exac.broadinstitute.org) reveals several (T672H, A629S, T621M,
T600M, T587I, R549H, R549C) detected in multiple individuals
that affect amino acids in the intracellular kinase domain that are
conserved in birds. By inference these mutations are likely to com-
promise receptor activity. If that is the case, ALSP may be the tip of
a less penetrant iceberg of CSF1R-dependent microglial dysfunction
(likely diagnosed as other disease entities in the absence of CSF1R
genotyping or autopsy22,150) or alternatively, these variants might
indeed produce complete loss of function but cause disease only in
homozygotes. Coding variants are considerably more common in the
extracellular domain but none affects contact amino acids involved
directly in ligand binding. However, Yeh et al.151 recently described
a CSF1R variant (H362R) with a high-allele frequency in the East
Asian population. They presented evidence that this change within
the receptor dimerization domain partly compromises signaling, but
others found that the variant did not prevent autophosphorylation.147
One of the two recent reports of the recessive disease26 pro-
moted the zebrafish as an alternative model of Csf1r deficiency, in
part because the mutation in inbred mice is apparently much more
severe than the human disease. It is certainly the case that the func-
tion of Csf1r in the generation of M𝜙s and microglia is conserved in
fish16,17,152 as it is in birds that provide an alternative tractable model
in which development can bemonitored in ovo.15 We have produced a
Csf1r deletion in chickens and observed the same severe growth retar-
dation (post-hatch) seen in mice and rats (DAH, A. Balic; unpublished).
One complexity ofworkingwith zebrafish, other than the quite distinct
skeletal andhematopoietic biology, is thatmuchof the genome is dupli-
cated and there are two Csf1r loci with partially redundant functions.
The generation of an allelic series with graded loss of 1 to 4 copies of
Csf1r indicated that microglial numbers are sensitive to Csf1r dosage
and further, that as in mice and rats (see above) some peripheral M𝜙
populations were less dependent upon Csf1r.152 However, as noted
above, 50% loss of Csf1r in the brain of rats and mice does not com-
promise microglial numbers. The phenotypes of mouse and rat Csf1r
mutations on inbred and outbred backgrounds show the same range of
phenotypes as observed in human patients and provide an informative
and relevant model to test therapies such as bone marrow transplan-
tation. The clear impact of genetic background implies the existence of
epistatic modifiers of disease phenotype, likely providing an additional
explanation for the diversity of age-of-onset. Indeed, one might con-
sider the possibility that consanguineous couples could also generate
homozygosity for epistaticmodifiers of the impact ofCSF1Rmutations
in their affected progeny.
Adult-onset patients with homozygous CSF1R mutations have not
been reported to exhibit the severe postnatal growth retardation seen
in mice and rats.25 We suggest that the impact of mutation on the
GH/IGF1 axis requires the complex loss of CSF1-CSF1R activity and
peripheral M𝜙 populations and it may have contributed to the more
severe cases with infant mortality. In any case, the absence of this phe-
notypic impact supports the argument above that osteopetrosis per se
is insufficient explanation for growth retardation. Otherwise the dif-
ferences from mutant animal phenotypes are not that great. It is clear
from the mouse and rat mutations of Csf1r that microglia and osteo-
clasts are CSF1R-dependent. Other populations that share CSF1R-
dependence with microglia, such as Langerhans cells, peritoneal M𝜙s,
and heart and kidney M𝜙s, have not been studied in either ALSP or
homozygous/compound heterozygousmutant patients. ALSP patients,
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who certainly do have residual CSF1R activity, do not exhibit the skele-
tal phenotypes described in the recessive disease but they do show
ectopic calcification in the brain.146 As discussed above, the osteo-
clast deficiency in outbredmouseCsf1r−/− mice resolveswith age, indi-
cating that there are other factors that can compensate for the loss
of CSF1R. Similarly, our Csf1rΔFIRE/ΔFIRE mice lack microglia but they
have normal M𝜙s and osteoclasts in the bone despite the lack of Csf1r
expression in those cells. We can conclude therefore that microglia
are likely more sensitive than osteoclasts to disruption of CSF1R sig-
nals. In simple terms, we suggest that the autosomal dominant and
recessive diseases associated with CSF1R mutations are part of the
same spectrum of CSF1R insufficiency, with ALSP patients retaining
enough CSF1R activity to maintain osteoclasts and most tissue M𝜙
populations. That said, the impact of the ALSP-associated mutations
on peripheral M𝜙 biology has not been adequately considered in dis-
secting disease mechanisms. Several recent studies have emphasized
the relationship between resident tissue M𝜙s and the peripheral ner-
vous system (e.g., ref. 153) and we have identified very large numbers
of M𝜙s in smooth and skeletal muscle1; loss of function of these cells
could potentially contribute to motor defects in ALSP patients.1 Kupf-
fer cells were apparently unaffected in the livers of ALSP patients149
but they are also relatively CSF1R-independent in animals.40 There is
clearly some impact of ALSP mutations in the periphery, since there is
a defect in the CSF1-dependent generation of so-called non-classical
monocytes in patients.154 So, further studies of peripheral M𝜙 popu-
lations in ALSP patients are needed in order to fully understand the
disease process.
2 CONCLUSIONS
In overview,we suggest thatmouseand ratmutationsprovide informa-
tive and predictivemodels of the pathology of humanCSF1Rdeficiency
provided account is taken of genetic background and the variable sen-
sitivity of different M𝜙 populations to CSF1R loss of function. The evi-
dence for functional expression of CSF1R in non-hematopoietic cells is
not compelling and accordingly all of the phenotypes associated with
mutation of CSF1R or its ligands can be attributed to their impacts on
mononuclear phagocyte biology. In keeping with that conclusion, all of
the pleiotropic impacts of a Csf1rmutation inmice can be overcome by
neonatal bone marrow transplantation.155,156 The rat Csf1r−/− model
with improved postnatal viability offers the opportunity to test thera-
pies thatmight reverse the adverse phenotypes of humanCSF1Rmuta-
tions later in postnatal development or even in adults. Transplantation
and other interventions proven efficacious in mouse and rat models
are likely to provide insight into the human condition and may offer
promise to patients with these rare diseases.
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